Trevena crushed as analysts count red flags in FDA’s review of its new pain med
The FDA put out its in-house assessment of Trevena’s new pain med, now up for review, and at first blush it’s not looking good for …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
